[Intermediate and long term clinical effects of uterine arterial embolization with sodium alginate microspheres in treatment of diffuse adenomyosis].
OBJECTIVE
To study intermediate and long term efficacy of uterine arterial embolization (UAE) with sodium alginate microspheres (KMG) at diameters 500-00 microm in treatment of diffuse adenomyosis.


METHODS
Totally 40 patients with standard diffuse adenomyosis were enrolled and treated with UAE. KMG at diameters 500-700 microm for vascular embolization were used to embolize the arteries. The degree of dysmenorrhea, amount of menorrhea and uterine volume, as well as the level of serum CA125, follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) were investigated before and after UAE.


RESULTS
The follow up rates were 100% (40/40), 100% (40/40), 80% (32/40), 68% (27/40), 58% (23/40) after uterine arterial UAE 12, 24, 36, 48 and 60 months respectively. The early, intermediate and long-term effective rates were 90% (36/40), 88% (28/32), 83% (19/23). The degree of dysmenorrhea, the amount of menorrhea and the uterine volume, as well as serum CA125 all decreased significantly 3 months after UAE at varying degrees (P < 0.05). Compared with other follow-up time, the degree of dysmenorrhea and the amount of menorrhea declined to their lowest point at 6 month after UAE (P < 0.01). Paralleled with the decrease of volume of uterine, serum CA125 also decreased significantly and reached the lowest level 12 months later compared with other follow-up times (P < 0.01). Even at the 12th month after UAE serum CA125 was not normal and FSH, LH and E2 did not change all the times after UAE, (P > 0.05). No recurrence was found during the 60 months after UAE.


CONCLUSIONS
KMG used in UAE at diameters 500-700 microm has good intermediate and long term effectiveness in treatment of diffuse adenomyosis with no side effects.
Duan
Ping
P
Department of Gynecology, Second Hospital of Wenzhou Medical College, Wenzhou 325027, China.
Cheng
Jing
J
Lin
Ming
M
Cai
Lian-Lian
LL
Hu
Zhe
Z
Jin
Shi-Xiang
SX
Hu
Ming-Pin
MP
D000328:Adult; D000464:Alginates / Q000008:administration & dosage / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D004715:Endometriosis / Q000473:pathology / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D020723:Glucuronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D006603:Hexuronic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008863:Microspheres; D016896:Treatment Outcome; D055988:Uterine Artery; D055357:Uterine Artery Embolization / Q000009:adverse effects / Q000379:methods*; D014591:Uterine Diseases / Q000473:pathology / Q000628:therapy*; D014592:Uterine Hemorrhage / Q000209:etiology; D014599:Uterus / Q000098:blood supply* / Q000187:drug effects / Q000473:pathology
D000464:Alginates; D018394:CA-125 Antigen; D006603:Hexuronic Acids; D020723:Glucuronic Acid